
NOTIFICATION TO SHAREHOLDERS OF ANNUAL GENERAL MEETING ON 9 JUNE 2016

DATE: May 4, 2016

London (United Kingdom) - The shareholders of Stallergenes Greer plc (the “Company”) (Euronext Paris: STAGR) are hereby informed that they are invited to attend the Annual General Meeting at Palais Brongniart, 28 Place de la Bourse, 75002 Paris - France, on 9 June 2016 at 2:00 p.m. (Paris time).

Notice of the meeting is available in the “Investors” section on the website of the Company at www.stallergenesgreer.com. It contains the draft resolutions proposed by the Board of Directors, the explanatory notes and the main conditions under which shareholders may participate, vote and exercise their rights.

All the documents at the disposal of the shareholders as part of the General Meeting are available at the registered office of the Company in London (1 Curzon Street, London W1J 5HD, United Kingdom) and in Antony (6 rue Alexis de Tocqueville, 92160 Antony, France) as well as in the “Investors” section on the Company’s website (www.stallergenesgreer.com), in “2016 General Meeting”.

ABOUT STALLERGENES GREER PLC

Headquartered in London (UK), Stallergenes Greer plc is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France).

Trading information:

Name: Stallergenes Greer
ISIN: GB00BZ21RF93 1 - Ticker: STAGR
ICB classification: 4577
Market: Euronext Paris regulated market

Additional information is available at <http://www.stallergenesgreer.com>

This document (including information incorporated by reference in this document), oral statements made and other information published by the Company contain statements that are or may be forward-looking with respect to the financial condition and/or results of operations and businesses of the Company. These statements can be identified by the use of forward-looking terminology such as "believe", "expects", "project", "estimated", "forecast", "should", "plan", "may" or the negative of any of these, or other variations thereof, or comparable terminology indicating expectations or beliefs concerning future events. These forward-looking statements include risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. These and other factors are more fully described in the Company's 2015 annual report published on 29 April 2016 on the Company's website (www.stallergenesgreer.com). Actual results may differ from those set forth in the forward-looking statements, due to various factors. Save as required by applicable law, neither the Company nor any other person assumes any obligation to update these forward-looking statements or to notify any person of any such update.

Contacts

Investor and analyst relations

Peter Bühler
 Chief Financial Officer
 Tel: +33 1 55 59 23 22
 Email: investorrelations@aresallergyco.com

Investor relations agency

FTI Consulting
 Arnaud de Cheffontaines
 Tel: +33 1 47 03 69 48
 Email: arnaud.decheffontaines@fticonsulting.com

Media relations

Lise Lemonnier
 Head of Global communications
 Tel: + 33 1 55 59 20 96
 Email: llemonnier@stallergenes.com

Media relations agency

Havas Worldwide Paris
 Jean-Baptiste Froville
 Tel: +33 1 58 47 95 39
 Email: jean-baptiste.froville@havasww.com